Swiss Intellectual Property and Competition Law. Volume IV: Patent Law and Know-how including Genetic Engineering, Software and Plant Variety Right Protection

Published: 10 May 2006

  • PEOPLE

    Thierry Calame
    Managing Partner, Co-Head of Intellectual Property

  • Expertise

    Intellectual Property

  • Details

    Number of pages
    1048 pages
    Publisher
    Helbing & Lichtenhahn Verlag
    Language
    German
    Price
    CHF 348.00
    ISBN number
    978-3-7190-2163-4

Thanks to its comprehensive treatment and systematic explanations of all Swiss intellectual property and competition laws, this book series has quickly become a valuable reference tool for the practitioner. Volume 4 (out of 11) covers patent law, including statutory subject matter and patentability requirements, inventor ship and ownership, obtaining the patent grant, the rights and limitations of the patent grant, infringement (claim interpretation and doctrine of equivalents), biotechnological and computer-implemented inventions, supplementary protection certificates, and patent information. Two separate chapters are dedicated to the protection of plant varieties and know-how, respectively.

Related publications

SEE ALL

Insights

Insights – 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights – 03.11.2025

Draft bill on communication platforms and search engines in Switzerland

Draft bill on communication platforms and search engines in Switzerland

SEE ALL
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}